RG002 / RinuaGene Biotech - LARVOL DELTA

Safety, Immunogenicity, and Efficacy of RG002, an mRNA-LNP-Based Therapeutic Targeting HPV 16/18 E2/E6/E7, in Patients with CIN2/3: Results from a Phase I and Expanded Clinical Study (ESMO 2026) - No abstract available

Clinical • P1 data • Oncology

First-in-Class mRNA-LNP Immunotherapy RG002 Induces Complete Lesion Regression and Viral Clearance in HPV 16/18 Associated CIN2/3: A Phase I Study (ESMO-Gynae 2026) - No abstract available

P1 data • Gynecologic Cancers

Rg002: An mRNA-LNP-based immunotherapy targeting HPV-16/18-related malignancies (AACR 2026) - "Based on promising early results, the protocol has been amended to enroll an additional 15-30 patients by January 2026. Updated results from over 40 patients, including Week 17 efficacy data for at least 20 patients, are expected in mid-April 2026.*"

Cervical Cancer • Oncology • IFNG

An Open, Phase I/II Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RG002 Injection, an mRNA Product, in Subjects with Human Papillomavirus (HPV) 16 and/or HPV18-Associated Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN23) (ChiCTR) - P1/2 | N=24 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Renjing (Suzhou) Biotechnology Co., Ltd

New P1/2 trial • Gynecology • Oncology

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 (clinicaltrials.gov) - P1/2 | N=39 | Not yet recruiting | Sponsor: RinuaGene Biotechnology Co., Ltd.

New P1/2 trial • Cervical Cancer • Gynecology • Infectious Disease • Oncology